journal article·2026-08Open access

Smart nanodrug delivery systems for treatment of endometrial cancer

Chengfeng Cai, Xiaochun Li, Xinyi Qiu, Yuqing Lin, Qiantong Chen, Jiahuan Zheng, Kaisong Yuan, Shaoqi Chen

Abstract

Endometrial cancer (EC) is a group of epithelial malignant tumors that occur in the endometrium. Traditional therapies in clinical practice often face multiple challenges, including tumor recurrence, local invasion, distant metastasis, the development of drug resistance, and significant toxic side effects. Nanoparticles (NPs) have unique size advantages and extensive modifiability. They can achieve precise targeting of diseases to reduce toxicity, increase efficacy, inhibit metastasis, and combat drug resistance. This has brought new hope for the treatment of EC. While most relevant reviews cover a wide spectrum of gynecological disorders, there remains a lack of detailed and systematic elaboration on the application of NPs in the therapy of EC. The present review focuses on the application value of nanodrug delivery systems (NDDSs) in the treatment of EC, summarizes representative nanomaterials developed for EC treatment, and highlights the advanced delivery strategies and corresponding therapeutic applications of NDDSs for EC. In the concluding section, we summarize the current limitations of NDDSs in the EC field, map out a translational path from bench to bedside, and highlight safety and efficacy as pivotal elements, aiming to provide practical solutions for future medical-technology innovation.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Endometrial and Cervical Cancer Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2. Cancer statistics, 2023
3. Cancer statistics, 2024
4. Advances in the management of endometrial cancer
5. NCCN Clinical Practice guidelines in oncology10.6004/jnccn.2023.0006 ↗
6. Adjuvant therapy for endometrial cancer10.3802/jgo.2014.25.2.136 ↗
7. Cancer nanomedicine: emerging strategies and therapeutic potentials10.3390/molecules28135145 ↗
8. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy10.1136/ijgc-2020-001822 ↗
9. Two pathogenetic types of endometrial carcinoma10.1016/0090-8258(83)90111-7 ↗
10. Classification of endometrial carcinoma: more than two types, the Lancet
11. Endometrial cancer: molecular markers and management of advanced stage disease10.1016/j.ygyno.2018.05.015 ↗
12. The landscape of microsatellite instability in colorectal and endometrial cancer genomes10.1016/j.cell.2013.10.015 ↗
13. Toxicity of targeted therapy: implications for response and impact of genetic polymorphisms10.1016/j.ctrv.2014.05.003 ↗
14. Targeted drug delivery strategies for precision medicines10.1038/s41578-020-00269-6 ↗
15. Drug resistance and combating drug resistance in cancer
16. Fertility-Sparing treatments in endometrial cancer: a comprehensive review on efficacy, oncological outcomes, and reproductive potential10.3390/medicina61030471 ↗
17. Oral nano-formulations for endocrine therapy of endometrioid adenocarcinomas
18. Recent advances in the bench-to-bedside translation of cancer nanomedicines10.1016/j.apsb.2024.12.007 ↗
19. Nano/Micromotors for cancer diagnosis and therapy: innovative designs to improve biocompatibility10.3390/pharmaceutics16010044 ↗
20. Nanobodies targeting the tumor microenvironment and their formulation as nanomedicines10.1186/s12943-025-02270-5 ↗
21. Development of tumor-evolution-targeted anticancer therapeutic nanomedicineEVT10.1016/j.chempr.2023.12.019 ↗
23. Engineering precision nanoparticles for drug delivery10.1038/s41573-020-0090-8 ↗
24. Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery10.1186/s12951-022-01605-4 ↗
25. Polymer nanoparticles advancements for gynecological cancers10.2147/IJN.S527023 ↗
26. A. Subramanian, A.V. Rau, H. Kaligotla, Surface modification of chitosan for selective surface–protein interac tion, Carbohydr. Polym. 66(3) 321-332. https://doi.org/10.1016/j.carbpol.2006.03.022.10.1016/j.carbpol.2006.03.022 ↗
27. Natural biodegradable polymers based nano-formulations for drug delivery: a review10.1016/j.ijpharm.2019.03.011 ↗
28. Cytocompatible chitosan-graft-mPEG-based 5-fluorouracil-loaded polymeric nanoparticles for tumor-targeted drug delivery10.1080/03639045.2017.1371741 ↗
29. Structurally reprogrammed modified citrus pectin (MCP) enables potentiated galectin-3 sequestration and injectable carboxymethyl chitosan/berberine hydrogel construction for osteoarthritis immunotherapy
30. Hyaluronic acid as a modern approach in anticancer therapy-review10.3390/ijms24010103 ↗
31. Hyaluronic acid-based nanocarriers for anticancer drug delivery10.3390/polym15102317 ↗
32. Hyaluronic acid: more than a carrier, having an overpowering extracellular and intracellular impact on cancer10.1016/j.carbpol.2023.121081 ↗
33. Stealth nanoparticles in oncology: facing the PEG dilemma10.1016/j.jconrel.2022.09.002 ↗
34. PEG‐Polymer encapsulated aggregation‐induced emission nanoparticles for tumor theranostics10.1002/adhm.202101036 ↗
35. PEG - a versatile conjugating ligand for drugs and drug delivery systems10.1016/j.jconrel.2014.06.046 ↗
36. PLGA-based nanoparticles: an overview of biomedical applications10.1016/j.jconrel.2012.01.043 ↗
37. Synthesis, characterization, biodegradation, and drug delivery application of biodegradable lactic/glycolic acid polymers: I. Synthesis and characterization10.1163/156856200743715 ↗
38. Synthesis, characterization, biodegradation, and drug delivery application of biodegradable lactic/glycolic acid polymers. Part II: biodegradation10.1163/156856201744425 ↗
39. Synthesis, characterization, biodegradation, and drug delivery application of biodegradable lactic/glycolic acid polymers: part III. Drug delivery application, Artificial cells, blood substitutes
40. Synthetically lethal nanoparticles for treatment of endometrial cancer10.1038/s41565-017-0009-7 ↗
41. Improved therapeutic effect of folate-decorated PLGA-PEG nanoparticles for endometrial carcinoma10.1016/j.bmc.2011.05.016 ↗
42. Recent trends on polycaprolactone as sustainable polymer-based drug delivery system in the treatment of cancer: biomedical applications and nanomedicine10.1016/j.ijpharm.2024.124734 ↗
43. The in vivo degradation, absorption and excretion of PCL-based implant10.1016/j.biomaterials.2005.09.019 ↗
44. PEG-PCL-based nanomedicines: a biodegradable drug delivery system and its application10.1016/j.jconrel.2017.05.028 ↗
45. PCL-PEtOx-based crystalline-core micelles for the targeted delivery of paclitaxel and Trabectedin in ovarian cancer therapy10.1016/j.actbio.2025.04.050 ↗
46. Development and evaluation of carboplatin-loaded PCL nanoparticles for intranasal delivery10.3109/10717544.2014.948643 ↗
47. Crucial role of PLGA nanoparticles in mitigating the amiodarone-induced pulmonary toxicity
48. PCL and PCL-based materials in biomedical applications10.1080/09205063.2017.1394711 ↗
49. Lipid nanoparticles─from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement10.1021/acsnano.1c04996 ↗
50. Liposomes: structure, composition, types, and clinical applications10.1016/j.heliyon.2022.e09394 ↗
51. Liposomes for tumor targeted therapy: a review10.3390/ijms24032643 ↗
52. Solid lipid nanoparticles in imaging, diagnostics and theranostics: a review of a decade of innovations and clinical applications
53. Lipid-based drug delivery systems: concepts and recent advances in transdermal applications10.3390/nano15171326 ↗
54. Biological applications of copper-containing materials
55. The copper age in cancer treatment: from copper metabolism to cuproptosis10.1016/j.pmatsci.2023.101145 ↗
56. The coppery age: copper (cu)‐involved nanotheranostics10.1002/advs.202001549 ↗
57. Copper induces cell death by targeting lipoylated TCA cycle proteins10.1126/science.abf0529 ↗
58. Enhanced tumor-specific disulfiram chemotherapy by in Situ Cu(2+) chelation-initiated nontoxicity-to-toxicity transition10.1021/jacs.9b03503 ↗
59. X-ray induced photodynamic therapy with copper-cysteamine nanoparticles in mice tumors10.1073/pnas.1900502116 ↗
60. Immunostimulatory effect of chitosan conjugated green copper oxide nanoparticles in tumor immunotherapy10.1016/j.cyto.2019.154958 ↗
61. Superparamagnetic superparticles for magnetic hyperthermia therapy: overcoming the particle size limit10.1021/acsami.4c22386 ↗
62. Reaction time-induced improvement in hyperthermia properties of cobalt ferrite nanoparticles with different sizes10.1016/j.matchemphys.2023.127773 ↗
63. Comparison of copper-based Cu-Ni and Cu-Fe nanoparticles synthesized via laser ablation for magnetic hyperthermia and antibacterial applications10.1016/j.physb.2022.414503 ↗
64. Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers10.2147/IJN.S30320 ↗
65. Imaging-guided precision hyperthermia with magnetic nanoparticles10.1038/s44222-024-00257-3 ↗
66. Superparamagnetic iron oxide nanoparticles drive miR-485-5p inhibition in glioma stem cells by silencing Tie1 expression10.7150/ijbs.42887 ↗
67. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites10.1111/jphp.13098 ↗
68. Ciprofloxacin derivative-loaded nanoparticles synergize with Paclitaxel against type II human endometrial cancer
69. Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy10.1016/j.bbcan.2020.188446 ↗
70. Passive and active drug targeting: drug delivery to tumors as an example10.1007/978-3-642-00477-3_1 ↗
71. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review10.1016/S0168-3659(99)00248-5 ↗
72. Analysis of nanoparticle delivery to tumours
73. Enhanced permeability and retention (EPR) effect: advances in nanomedicine for improved tumor targeting
74. Single-cell transcriptome profiles the heterogeneity of tumor cells and microenvironments for different pathological endometrial cancer and identifies specific sensitive drugs10.1038/s41419-024-06960-8 ↗
75. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics10.1016/j.ejps.2012.12.006 ↗
76. Recent advances in targeted drug delivery strategy for enhancing oncotherapy10.3390/pharmaceutics15092233 ↗
77. The entry of nanoparticles into solid tumours10.1038/s41563-019-0566-2 ↗
78. The prognostic value of tumor microenvironment in endometrioid type endometrial cancer: effect of CD44 on oncologic outcome10.1002/ijgo.16071 ↗
79. Hyaluronic acid-functionalized nanomicelles enhance SAHA efficacy in 3D endometrial cancer models10.3390/cancers13164032 ↗
80. Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine10.3109/1061186X.2015.1052072 ↗
81. Hyaluronan-CD44 interactions as potential targets for cancer therapy10.1111/j.1742-4658.2011.08071.x ↗
82. CD44 expression in curettage and postoperative specimens of endometrial cancer10.1007/s00404-014-3407-1 ↗
83. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay10.1016/j.ab.2004.12.026 ↗
84. Proteomic and functional characterization of intra-tumor heterogeneity in human endometrial cancer
85. Progress and challenges towards targeted delivery of cancer therapeutics10.1038/s41467-018-03705-y ↗
86. Nanoparticle-protein corona complexes govern the biological fates and functions of nanoparticles10.1039/c3tb21526a ↗
87. Immunological properties of engineered nanomaterials10.1038/nnano.2007.223 ↗
88. Xiang · 2019
89. Ultrasound meets nanomedicine: towards disease treatment and medical imaging10.1007/s00604-025-07042-y ↗
90. Tumor microenvironment-responsive polymer delivery platforms for cancer therapy
91. Highly loaded erlotinib tubular micromotor for targeted drug delivery, pH responsive release and ultrasound tracking: a three-in-one micromachine
92. Cancer cell metabolism and antitumour immunity10.1038/s41577-024-01026-4 ↗
93. The updated landscape of tumor microenvironment and drug repurposing10.1038/s41392-020-00280-x ↗
94. Stimuli-responsive nanomaterials for application in antitumor therapy and drug delivery10.3390/pharmaceutics12070630 ↗
95. Ultra pH-sensitive polymeric nanovesicles co-deliver doxorubicin and navitoclax for synergetic therapy of endometrial carcinoma10.1039/D0BM00112K ↗
96. Chin
97. Enhancing of nanocatalyst-driven chemodynaminc therapy for endometrial cancer cells through inhibition of PINK1/Parkin-Mediated mitophagy10.2147/IJN.S329341 ↗
98. Stimulus-responsive viral vectors for controlled delivery of therapeutics10.1016/j.jconrel.2017.08.021 ↗
99. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple10.1016/S0891-5849(01)00480-4 ↗
100. Targeted drug delivery in gynaecology: the first uterine pass effect10.1093/humrep/12.5.1073 ↗